ITOC-1 Immunotherapy of Cancer Conference
March 12-14, 2014
Munich, Germany
SITC partnered with Biotherapy Development Association (BDA) on the first European meeting intending to provide a platform for preclinical and clinical researchers in the field of cancer immunotherapy. The concept was timely and necessary as agents have been licensed and arrived in clinical practice and many more similar drugs are expected to follow.
This scientific conference discussed the latest and future developments in immunotherapy. The committee selected some highly interesting abstracts that influence the direction of immunotherapy in cancer. The Conference was open to drug developers from academia and industry, clinicians, immunologists and scientists.
The goal of the conference was to provide a forum for discussion of early clinical drug development and address its unique challenges of drug development. The program focused on topics such as immunomodulatory agents, anti-cancer vaccines and monoclonal antibodies with special emphasis on translational research and biomarker development.
Meeting Objectives
- To bring together preclinical and clinical scientists to translate molecular targets into effective cancer therapy
- To provide opportunities to present scientific data in relation to early clinical trials
- To encourage new approaches for translational research and biomarkers
- To address the challenges of immunotherapy
- To bring together a multi-stakeholder audience and foster productive collaboration among investigators.
